AVTX
AVTX
Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
1
$13K
Insider Sales
23
$8.50M
Total Volume
$8.51M
44 transactions
Net Activity
$8.49M
Net selling
Sentiment Rating
Moderate DistributionCEO Conviction Index
No Recent Signal
Key Drivers
- •Heavy distribution: sales represent 100% of total transaction value.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
Sullivan Christopher Ryan
CFO
$3.72M total
Doyle Mittie
Chief Medical Officer
$2.98M total
Varki Paul
GC
$1.51M total
Multiple Insiders
S - Sale+OE Insiders
$1.00M total
Goldman Jonathan
Dir
$163K total
Quick Actions
AVTX has an insider buy conviction of 0%, compared to the Unknown sector buy average of 6%.
Over the last 90 days, corporate insiders at AVTX (AVTX) engaged in a total of 44 transactions reported via SEC Form 4 filings. Among these, 1 were open-market purchases and 23 were sales. The total volume of insider trading reached $8.51M.
The net insider activity for AVTX shows a net selling bias of $8.49M. This activity represents a 0% buy ratio, suggesting that insiders are currently bearish on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Sale by Doyle Mittie (Chief Medical Officer), who traded 108.2K shares valued at $2.23M on May 5, 2026.
Avalo Therapeutics Stock Price Forecast. Should You Buy AVTX?
AVTX May 2027 15.000 call (AVTX270521C00015000) Stock Price, News, Quote & History
AVTX - Avalo Therapeutics Inc Stock Price and Quote
AVTX Forecast — Price Target — Prediction for 2027
Price-Driven Insight from (AVTX) for Rule-Based Strategy
Here's Why Avalo Therapeutics (AVTX) is Poised for a Turnaround After Losing 40.4% in 4 Weeks
FAQs About AVTX Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for AVTX.